IBDEI10V ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,16436,2)
 ;;=^5001814
 ;;^UTILITY(U,$J,358.3,16437,0)
 ;;=C92.A0^^88^879^12
 ;;^UTILITY(U,$J,358.3,16437,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16437,1,3,0)
 ;;=3^Acute Myeloid Leukemia w/ Multilin Dysplasia,Not in Remission
 ;;^UTILITY(U,$J,358.3,16437,1,4,0)
 ;;=4^C92.A0
 ;;^UTILITY(U,$J,358.3,16437,2)
 ;;=^5001813
 ;;^UTILITY(U,$J,358.3,16438,0)
 ;;=C92.51^^88^879^13
 ;;^UTILITY(U,$J,358.3,16438,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16438,1,3,0)
 ;;=3^Acute Myelomonocytic Leukemia,In Remission
 ;;^UTILITY(U,$J,358.3,16438,1,4,0)
 ;;=4^C92.51
 ;;^UTILITY(U,$J,358.3,16438,2)
 ;;=^5001805
 ;;^UTILITY(U,$J,358.3,16439,0)
 ;;=C92.50^^88^879^14
 ;;^UTILITY(U,$J,358.3,16439,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16439,1,3,0)
 ;;=3^Acute Myelomonocytic Leukemia,Not in Remission
 ;;^UTILITY(U,$J,358.3,16439,1,4,0)
 ;;=4^C92.50
 ;;^UTILITY(U,$J,358.3,16439,2)
 ;;=^5001804
 ;;^UTILITY(U,$J,358.3,16440,0)
 ;;=C94.40^^88^879^17
 ;;^UTILITY(U,$J,358.3,16440,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16440,1,3,0)
 ;;=3^Acute Panmyelosis w/ Myelofibrosis,Not in Remission
 ;;^UTILITY(U,$J,358.3,16440,1,4,0)
 ;;=4^C94.40
 ;;^UTILITY(U,$J,358.3,16440,2)
 ;;=^5001843
 ;;^UTILITY(U,$J,358.3,16441,0)
 ;;=C94.42^^88^879^15
 ;;^UTILITY(U,$J,358.3,16441,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16441,1,3,0)
 ;;=3^Acute Panmyelosis w/ Myelofibrosis,In Relapse
 ;;^UTILITY(U,$J,358.3,16441,1,4,0)
 ;;=4^C94.42
 ;;^UTILITY(U,$J,358.3,16441,2)
 ;;=^5001845
 ;;^UTILITY(U,$J,358.3,16442,0)
 ;;=C94.41^^88^879^16
 ;;^UTILITY(U,$J,358.3,16442,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16442,1,3,0)
 ;;=3^Acute Panmyelosis w/ Myelofibrosis,In Remission
 ;;^UTILITY(U,$J,358.3,16442,1,4,0)
 ;;=4^C94.41
 ;;^UTILITY(U,$J,358.3,16442,2)
 ;;=^5001844
 ;;^UTILITY(U,$J,358.3,16443,0)
 ;;=D62.^^88^879^18
 ;;^UTILITY(U,$J,358.3,16443,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16443,1,3,0)
 ;;=3^Acute Posthemorrhagic Anemia
 ;;^UTILITY(U,$J,358.3,16443,1,4,0)
 ;;=4^D62.
 ;;^UTILITY(U,$J,358.3,16443,2)
 ;;=^267986
 ;;^UTILITY(U,$J,358.3,16444,0)
 ;;=C92.41^^88^879^19
 ;;^UTILITY(U,$J,358.3,16444,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16444,1,3,0)
 ;;=3^Acute Promyelocytic Leukemia,In Remission
 ;;^UTILITY(U,$J,358.3,16444,1,4,0)
 ;;=4^C92.41
 ;;^UTILITY(U,$J,358.3,16444,2)
 ;;=^5001802
 ;;^UTILITY(U,$J,358.3,16445,0)
 ;;=C92.40^^88^879^20
 ;;^UTILITY(U,$J,358.3,16445,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16445,1,3,0)
 ;;=3^Acute Promyelocytic Leukemia,Not in Remission
 ;;^UTILITY(U,$J,358.3,16445,1,4,0)
 ;;=4^C92.40
 ;;^UTILITY(U,$J,358.3,16445,2)
 ;;=^5001801
 ;;^UTILITY(U,$J,358.3,16446,0)
 ;;=D56.0^^88^879^21
 ;;^UTILITY(U,$J,358.3,16446,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16446,1,3,0)
 ;;=3^Alpha Thalassemia
 ;;^UTILITY(U,$J,358.3,16446,1,4,0)
 ;;=4^D56.0
 ;;^UTILITY(U,$J,358.3,16446,2)
 ;;=^340494
 ;;^UTILITY(U,$J,358.3,16447,0)
 ;;=D63.1^^88^879^23
 ;;^UTILITY(U,$J,358.3,16447,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16447,1,3,0)
 ;;=3^Anemia in Chronic Kidney Disease
 ;;^UTILITY(U,$J,358.3,16447,1,4,0)
 ;;=4^D63.1
 ;;^UTILITY(U,$J,358.3,16447,2)
 ;;=^332908
 ;;^UTILITY(U,$J,358.3,16448,0)
 ;;=D63.0^^88^879^24
 ;;^UTILITY(U,$J,358.3,16448,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16448,1,3,0)
 ;;=3^Anemia in Neoplastic Disease
 ;;^UTILITY(U,$J,358.3,16448,1,4,0)
 ;;=4^D63.0
